[The role of Stratus OCT in anti-VEGF therapy. Qualitative and quantitative assessment of neovascular AMD]

Ophthalmologe. 2008 Jul;105(7):650-5. doi: 10.1007/s00347-007-1639-1.
[Article in German]


Background: The evaluation of OCT3 during anti-VEGF therapy.

Methods: A total of 29 patients with choroidal neovascularization secondary to AMD received 3 intravitreal injections of ranibizumab. OCT examination and visual acuity testing (ETDRS) were performed before therapy onset, after 1 week and after 1, 2 and 3 months.

Results: The central retinal thickness (CRT) was assessed correctly by OCT in 128 out of 145 measurements. There was a distinct (84%) but not significant correlation between decrease in central retinal thickness and increase in visual acuity. Incorrect retinal layer segmentation and inadequate CRT measurements were a significant technical limitation.

Conclusion: During anti-VEGF therapy, OCT allows documentation and quantification of morphologic retinal changes and in most cases also for an estimation of functional improvement.

Publication types

  • Controlled Clinical Trial
  • English Abstract

MeSH terms

  • Aged
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Corneal Neovascularization / diagnosis*
  • Corneal Neovascularization / drug therapy*
  • Corneal Neovascularization / etiology
  • Female
  • Humans
  • Image Interpretation, Computer-Assisted / methods*
  • Macular Degeneration / complications
  • Macular Degeneration / diagnosis*
  • Macular Degeneration / drug therapy*
  • Male
  • Prognosis
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / immunology*


  • Antibodies, Monoclonal
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A